Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3

Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer’s 36th Annual Healthcare Life Sciences ...